- Effectively implementing a risk-based approach to vendor oversight
- How to right-size vendor oversight for our high-risk activities being outsourced
- Why is vendor oversight important and what regulations drive this
- Recognizing the importance of cross-functional collaboration to best manage vendor activity
Archives: Agenda
Chair’s opening remarks
Chair’s opening remarks
Chair’s opening remarks
END OF DAY 1 AND NETWORKING DRINKS
Sponsored by EmVenio
Join us in the atrium for a drinks reception
END OF DAY 1 AND NETWORKING DRINKS
Sponsored by EmVenio
Join us in the atrium for a drinks reception
Reaching underrepresented patients for trials in the current climate
- Why inclusive research is a business and clinical imperative
- How to continue the work in the current climate
- Increasing focus on US enrollment
- Five principles of data driven inclusive research
Managing Drug Development: A Biotech Company Perspective
- Engaging right CROs/CDMOs
- GXP compliance
- Budget, timeline, and conflicts
Patient advocacy and incorporating patient perspectives early on in a small biotech
- Developing relationships with advocacy groups and patient communities from early stages
- How does patient advocacy differ at biotechs vs large pharma?
- Integrating patient insights into your study to ensure patients remain the priority throughout your trial
Making AI approachable
- Move past the hype: Treat AI as a strategic enabler, not a technical hurdle.
- Conversing with data: Use AI to interact with insights rather than just manage information.
- Practical toolkit: Combine everyday assistants with specialized models for rapid document synthesis and cross-referencing.
- Incremental adoption: Integrate AI capabilities gradually without overwhelming learning requirements.
- Outcome: Empower teams to enhance expertise and decision-making with AI.